SCHEMBL1997569

SCHEMBL1997569

O=C1CN(Cc2ccc(-c3cccc(CN4CCCCC4)c3)cc2)C(=O)N1CC(F)F

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.49
CYP2C19 P33261 1/20 0.49
HRH3 Q9Y5N1 6/20 0.48
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HRH4 Q9H3N8 1/20 0.43
ENPP2 Q13822 1/20 0.41
HDAC6 Q9UBN7 2/20 0.40
MCHR1 Q99705 2/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
NR1H2 P55055 1/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
HTR2C P28335 1/20 0.39
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1998795 0.90 CYP2D6 (0.49) CYP2D6CYP2C19HRH3HRH4ENPP2
SCHEMBL1998174 0.83 CYP2D6 (0.48) CYP2D6CYP2C19HRH3HRH4ENPP2
SCHEMBL1994800 0.82 HRH3 (0.41) CYP2D6CYP2C19HRH3ALDH1A1HRH4
SCHEMBL840115 0.81 HRH3 (0.41) CYP2D6CYP2C19HRH3HRH4ENPP2
SCHEMBL1997193 0.80 HRH3 (0.46) CYP2D6CYP2C19HRH3ALDH1A1SMN1; SMN2
SCHEMBL2002675 0.79 DHODH (0.43) CYP2D6CYP2C19HRH3ENPP2HDAC6
SCHEMBL1997243 0.78 HRH3 (0.44) CYP2D6CYP2C19HRH3ALDH1A1SMN1; SMN2
SCHEMBL840699 0.77 HRH3 (0.41) CYP2D6CYP2C19HRH3ALDH1A1HRH4
SCHEMBL1998338 0.75 MCHR1 (0.40) CYP2D6CYP2C19HRH3ENPP2HDAC6
SCHEMBL1997677 0.75 ENPP2 (0.39) CYP2D6CYP2C19HRH3ENPP2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US claimed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US claimed
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP disclosed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US disclosed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE OPRM1, OR10J3, OPRD1 CYP2D6 452/4885CYP2C19 1442/4885HRH3 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.